Skip Navigation

JNCI Journal of the National Cancer Institute 1991 83(17):1245-1248; doi:10.1093/jnci/83.17.1245
© 1991 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Austin, E. B.
Right arrow Articles by Durrant, L. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Austin, E. B.
Right arrow Articles by Durrant, L. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 83, No. 17, 1245-1248, September 4, 1991
© 1991 Oxford University Press

Induction of Delayed Hypersensitivity to Human Tumor Cells With a Human Monoclonal Anti-idiotypic Antibody

E. B. Austin*,1, R. A. Robins1, R. W. Baldwin1, L. G. Durrant1

1Cancer Research Campaign Laboratories, Nottingham University Nottingham, U.K.

*Correspondance to: E. B. Austin, M.D., Cancer Research Campaign Laboratories, Nottingham University, Nottingham NG7 2RD, UK.

There is considerable interest in the development of anti-idiotypic antibodies as vaccines in a number of diseases, including cancer. We have developed a human anti-idiotypic monoclonal antibody (105AD7) which binds at or very near to the binding site of mouse antitumor monoclonal antibody 791T/36. The 791T/36 antibody binds to a tumor-associated antigen (gp72) expressed on a number of human tumors, including colorectal and ovarian carcinomas and osteogenic sarcoma. This study shows that, in rats and mice, 105AD7 induces delayedtype hypersensitivity to human tumor cells bearing the gp72 antigen. Local transfer of delayed hypersensitivity was also demonstrated using lymphocytes from mice primed with 105AD7. These findings show that the human monoclonal anti-idiotypic antibody 105AD7 is likely to induce cellular immune responses to tumors in cancer patients. [J Natl Cancer Inst 83: 1245–1248, 1991]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
G. J. Ullenhag, I. Spendlove, N. F.S. Watson, A. A. Indar, M. Dube, R. A. Robins, C. Maxwell-Armstrong, J. H. Scholefield, and L. G. Durrant
A Neoadjuvant/Adjuvant Randomized Trial of Colorectal Cancer Patients Vaccinated with an Anti-Idiotypic Antibody, 105AD7, Mimicking CD55
Clin. Cancer Res., December 15, 2006; 12(24): 7389 - 7396.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. G. Durrant, C. Maxwell-Armstrong, D. Buckley, S. Amin, R. A. Robins, J. Carmichael, and J. H. Scholefield
A Neoadjuvant Clinical Trial in Colorectal Cancer Patients of the Human Anti-Idiotypic Antibody 105AD7, Which Mimics CD55
Clin. Cancer Res., February 1, 2000; 6(2): 422 - 430.
[Abstract] [Full Text]

Home page
 GutHome page
C A Maxwell-Armstrong, L G Durrant, R A Robins, A M Galvin, J H Scholefield, and J D Hardcastle
Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7
Gut, October 1, 1999; 45(4): 593 - 598.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Spendlove, L. Li, J. Carmichael, and L. G. Durrant
Decay Accelerating Factor (CD55): A Target for Cancer Vaccines?
Cancer Res., May 1, 1999; 59(10): 2282 - 2286.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.